1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Dawnrays Pharmaceutical Holdings Ltd.

Dawnrays Pharmaceutical Holdings Ltd.

HHKEX:2348
0.96
HKD
+0.01
(+0.53%)
1.83BMarket Cap
Mar 19Next Earn
Dawnrays Pharmaceutical Holdings Ltd.
HKEX:2348
(Hong Kong Exchange)

Recent

price

0.96

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.81
0.68
0.54
0.57
0.49
0.61
0.51
0.55
0.6
0.6
0.66
0.78
0.85
0.77
0.7
0.82
- -
Revenue per Share
0.11
0.09
0.07
0.1
0.13
0.19
0.17
0.18
0.19
0.16
0.17
0.24
0.24
0.22
0.38
0.14
- -
Basic EPS, GAAP
0.11
-0.04
0.06
0.09
0.2
0.16
0.18
0.23
0.14
0.11
0.05
-0.01
0.14
0.08
0.03
0.16
- -
Free Cash Flow per Basic Share
0.03
0.04
0.03
0.03
0.04
0.05
0.06
0.06
0.13
0.07
0.05
0.1
0.07
0.08
0.07
0.09
- -
Dividend per Share
0.52
0.58
0.61
0.68
0.77
0.92
1.02
1.14
1.21
1.3
1.44
1.59
1.76
1.9
2.21
2.25
2.25
Book Value per Share
0.49
0.54
0.57
0.64
0.74
0.88
0.98
1.09
1.15
0.99
1.06
1.24
1.4
1.55
1.85
1.91
1.91
Tangible Book Value per Share
1,586
1,596
1,599
1,603
1,611
1,608
1,605
1,595
1,586
1,575
1,545
1,498
1,499
1,500
1,505
1,503
1,503
Basic Weighted Avg Shares
1,287
1,081
857
915
784
985
824
882
949
950
1,024
1,165
1,278
1,151
1,060
1,231
- -
Sales/Revenue/Turnover
15.93
19.69
20.13
25.45
38.53
40.98
42.52
44.76
43.53
33.35
32.82
34.07
35.09
38.42
34.7
24.55
- -
Operating Margin (%)
26
29
30
35
46
54
53
53
52
55
60
58
66
84
107
120
- -
Depreciation Expense
167
146
115
153
205
302
266
293
304
255
268
358
358
326
565
214
- -
Net Income, GAAP
20.13
18.35
20.83
18.98
20.76
19.88
20.22
19.89
19.54
18.7
20.07
19.38
18.83
22.07
11.65
15.43
- -
Effective Tax Rate (%)
12.97
13.53
13.37
16.73
26.17
30.68
32.26
33.2
32.03
26.89
26.18
30.74
28.02
28.32
53.28
17.38
- -
Profit Margin (%)
400
365
359
423
583
849
1,042
1,207
1,390
1,096
1,069
814
812
1,051
1,648
1,800
1,800
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
3
2
2
- -
- -
4
- -
- -
LT Debt
835
919
982
1,092
1,248
1,474
1,637
1,806
1,921
2,026
2,184
2,398
2,650
2,859
3,327
3,385
3,385
Total Equity
20.17
17.94
10.04
11.52
13.87
18.95
17.6
18
17.57
11.41
11.74
15.92
15.12
11.68
16.75
5.21
- -
Return on Invested Capital (%)
20.8
15.46
10.62
12.36
14.94
20.79
17.01
16.97
16.36
12.47
12.42
15.74
14.2
11.71
17.99
6.37
- -
Return on Capital (%)
21.58
16.68
12.05
14.76
17.53
22.2
17.1
17.02
16.31
12.94
12.78
15.74
14.26
11.86
18.29
6.38
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
31
9
77
LT Borrowings
- -
- -
- -
LT Finance Leases
4
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,502
1,503
1,503
Market Capitalization
1,722
1,701
1,648

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
2,202
2,135
2,294
Cash, Cash Equivalents & STI
1,365
1,400
1,577
Accounts Receivable, Net
122
124
143
Inventories
308
254
215
Total Current Liabilities
555
447
494
Payables & Accruals
- -
- -
- -
ST Debt
31
9
77
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.73%
9.26%
1.75%
Free Cash Flow
-207.32%
-399.43%
429.47%
Net Income, GAAP
2.67%
7.15%
-62.13%
Sales/Revenue/Turnover
2.79%
4.34%
16.09%
Total Cash Common Dividend
15.56%
15.53%
19.52%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1,151
2024
- -
- -
1,060
2025
- -
- -
1,231

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.22
2024
- -
- -
0.38
2025
- -
- -
0.14

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.08
2024
- -
- -
0.07
2025
- -
- -
0.09
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Dawnrays Pharmaceutical (Holdings) Limited functions as an investment holding enterprise, primarily engaging in the development, manufacturing, and distribution of generic pharmaceutical products across Mainland China and various international markets. The company’s operations are segmented into two key areas: Finished Drugs, which serves as its main source of revenue, and Intermediates and Bulk Medicines. Its product portfolio encompasses a wide array of cephalosporin antibiotics, including pharmaceutical intermediates, bulk active ingredients, injectable powders, and oral antibiotic formulations. Additionally, Dawnrays provides specialized medications addressing conditions related to the cardiovascular system, anti-hepatitis B virus, anti-allergic responses, digestive health, urinary tract issues, and endocrine disorders, available in forms such as tablets, capsules, and granules. A distinguishing feature of the company is its comprehensive vertically integrated approach to cephalosporin antibiotic production. Founded in 1995, the firm’s headquarters are situated in Wan Chai, Hong Kong. Dawnrays Pharmaceutical (Holdings) Limited operates as a subsidiary of Fortune United Group Limited.